The method thus offers a useful supplement to conventional systematic review methods.”
“Background: Beclometasone dipropionate (BDP) is a relatively new topically acting oral steroid to treat mild to moderately active ulcerative AP24534 clinical trial colitis (UC). We estimate that 20,000 patients have received oral BDP in Spain in the last two years. Our aim was to evaluate the efficacy and safety of oral BDP in clinical practice.
Methods: Retrospective and multicenter study that included 434 patients with active UC treated with BDP. The partial Mayo Clinic score (pMS, 0-9) was used to measure disease activity. Remission was defined as post-treatment pMS of 0 or 1; response as a decrease in pMS of 3 points or 2 points
and >30%, and failure as lack of remission or response.
Results: Dihydrotestosterone supplier BDP dose was 5 mg/day in 88% of patients and mean treatment duration was 6.2 weeks. BDP achieved remission in 44.4%, response in 22.3% and failed in 33.2% of patients. Mean pMS decreased
from 4.9 +/- 1.3 to 2.4 +/- 2.3 (p<0.0001). Remission rate was higher in mild and moderate than in severe UC (p<0.043) and tended to be higher in left-sided and extensive UC than in proctitis (p<0.06). Failure was less frequent in patients treated for >4 weeks (p<0.02). Mild adverse events were reported in 7.6% of patients.
Conclusion: BDP induces response or remission in two thirds of active UC patients, with a good safety profile. Patients with mild to moderate, left-sided or extensive UC, receiving BDP for more than 4 weeks are most likely to benefit from this treatment. (C) 2010 European Crohn’s and Colitis Organisation. Published by Elsevier B.V. All rights reserved.”
“Phytochemical investigation of CHCl3:MeOH (1:1) extract from the rhizomes of Nardostachys jatamansi led to the isolation of two new sesquiterpenoids (5 and 6), along with six known compounds (1-4, 7, 4EGI-1 price and 8). The structures of two new compounds were established using IR, MS, 1D, and 2D NMR
techniques. In addition, all the isolates were tested for their cytotoxicities against the A549 (lung cancer), DU-145 (prostate cancer), MCF-7 (breast cancer), and SK-N-SH (neuroblastoma).”
“One of the objectives in the treatment of the inflammatory bowel disease (IBD) is improving the patients quality of life. However, we do not dispose of validated criteria to determine the questionnaire’s scoring threshold that has to be reached in order to be able to assert that the patients quality of life has normalized.
Objective: To determine the normality punctuation cutoff in the IBD specific quality of life questionnaire IBDQ-36.
Method: Cross-sectional study in a random sample of IBD patients, who have completed the questionnaires IBDQ-36 and EuroQol-5D. The IBDQ-36 normality was calculated according to its equivalence with the EuroQol-5D tariff >= 0.90, which corresponds to the 95% CI of the average obtained in a Spanish general population.
Results: 218 patients were included.